Community Healthcare Trust Reports 2025 Results, Highlights Strong Acquisition Pipeline and Dividend Increase
summarizeSummary
Community Healthcare Trust Inc. reported a return to net income in 2025, driven by increased rental income and strategic acquisitions, while also disclosing a significant future acquisition pipeline and a dividend increase.
check_boxKey Events
-
Return to Profitability
The company reported net income of $5.1 million for the year ended December 31, 2025, a significant improvement from a net loss of $3.18 million in 2024.
-
Substantial Acquisition Pipeline
Community Healthcare Trust has five properties under definitive purchase agreements for an aggregate expected purchase price of $122.5 million, representing a significant growth opportunity for 2026 and 2027.
-
Dividend Increase Declared
The Board of Directors declared a quarterly common stock dividend of $0.4775 per share, payable March 4, 2026, reflecting a slight increase from previous quarters.
-
Credit Loss Reserves and Interest Rate Risk
The company recorded $8.7 million in credit loss reserves in 2025 for notes receivable with a geriatric inpatient behavioral hospital tenant, fully reserving these notes. Additionally, $75.0 million of interest rate swaps are set to expire in March 2026, exposing that portion of the revolving credit facility to higher variable interest rates (5.4% vs. 3.8% fixed).
auto_awesomeAnalysis
Community Healthcare Trust Inc.'s 2025 annual report indicates a return to profitability and a robust acquisition pipeline, signaling potential for future growth. However, the company continues to grapple with credit loss reserves related to a specific tenant and faces increased interest rate exposure as significant swaps expire. Investors should weigh the positive growth prospects and dividend increase against these financial headwinds and the potential impact of higher borrowing costs.
At the time of this filing, CHCT was trading at $18.02 on NYSE in the Real Estate & Construction sector, with a market capitalization of approximately $502.2M. The 52-week trading range was $13.23 to $20.28. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.